Adaptimmune designs and delivers cell therapies for people with cancer, with three products in clinical trials across various solid tumor indications, and a deep pre-clinical pipeline. The Company has reported durable responses in synovial sarcoma, and initial responses in head and neck, lung, esophagogastric junction, and melanoma cancers, with SPEAR T-cells targeting MAGE-A4. Data from the Phase 2 SPEARHEAD-1 trial (Abs. #11504), with afamitresgene autoleucel (MAGE-A4 targeted SPEAR T-cells) in synovial sarcoma and MRCLS, will be presented during the sarcoma session.
Additional Info
Will your company display a new product or promote a new indication/enhanced feature(s) for an existing product in your booth?
No